Lipid-Bound Sialic Acid (LSA) In Liver Diseases of Different Etiologies

Annals of Hepatology

Volumn 10, Issue 2, 2011, Pages 150-154

  Chrostek, Lech ^a   Cylwik, Bogdan ^a   Panasiuk, Anatol ^a   Brodowska Adamusiak, Dorota ^a   Gruszewska, Ewa ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Glycosylation; Lipid bound sialic acid; Liver diseases; Sialylation

Indexed keywords

ALPHA FETOPROTEIN; GLYCAN; LIPID; SIALIC ACID;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER CANCER; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; SIALYLATION; TOXIC HEPATITIS;

EID: 79956029783     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31563-7     Document Type: Article

References (16)

1. Schauer R, Kelm S, Reuter G, Roggentin P, Shaw L. Biochemistry and role of sialic acid. In: Rosenberg A (ed.). Biology of the sialic acids. New York: Plenum Press; 1995, p. 7-47.
2. Millar JS, Anber V, Shepherd J, Packard CJ. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions. Atherosclerosis 1999; 145: 253-60.
3. Marmillot P, Rao MN, Liu QH, Lakshman MR. Desialylation of human apolipoprotein E decreases its binding to human high-density lipoprotein and its ability to deliver estrified cholesterol to the liver. Metabolism 1999; 48: 1184-92.
4. Sillanaukee P, Ponnio M, Jaaskelainen IP. Occurrence of sialic acid in healthy humans and different disorders. Eur J Clin Invest 1999; 29: 413-25.
5. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberg-he H. Alteration of protein glycosylation in liver diseases. J Hepatol 2009; 50: 592-603.
6. Senn JH, Sellin S, Fitzke E, Stehle T, Häussinger D, Wie-land H, Gerok W. Biosynthesis and excretion of ganglio-sides by isolated perfused rat liver. Eur J Biochem 1992; 205: 809-14.
7. Senn HJ, Orth M, Fitzke E, Wieland H, Gerok W. Ganglio-sides in normal human serum. Concentration, pattern and transport by lipoproteins. Eur J Biochem 1989; 181: 657-62.
8. Senn HJ, Orth M, Fitzke E, Schölmerich J, Köster W, Wieland H, Gerok W. Altered concentrations, pattern and distribution in lipoproteins of serum gangliosides in liver diseases of different etiologies. J Hepatol 1990; 11: 290-6.
9. Katopodis N, Stock CC. Improved method to determine li-pid-bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol 1980; 30: 171-80.
10. Schutter EM, Visser JJ, van Kamp GJ, Mensdorff-Pouilly S, van Dijk W, Hilgers J, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a marker for malignancy. A review of the literature. Tumor Biol 1992; 13: 121-32.
11. Arif S, Haq N, Hanif R, Khan AS, Rehman J, Mufti TA. Variations of serum sialic acid level in liver cirrhosis. J Ayub Med Coll Abbottabad 2005; 17: 54-7.
12. Matsuzaki S, Itakura M, Iwamura K, Kamiguchi H. Serum sialic acid levels in liver cirrhosis and liver cancer. Jpn J Gastro-Enterol 1981; 78: 2395-401.
13. Seidel D. Lipoproteins in liver disease. J Clin Chem Clin Biochem 1987; 25: 541-51.
14. Dabelic S, Flögel M, Maravic G, Lauc G. Stress causes tissue-specific changes in the sialyltransferase activity. Z Naturforsch C 2004; 59: 276-80.
15. Stefenelli N, Klotz H, Engel A, Bauer P. Serum sialic acid in malignant tumors, bacterial infections, and chronic liver diseases. J Cancer Res Clin Oncol 1985; 109: 55-9.
16. Cylwik B, Chrostek L, Panasiuk A, Szmitkowski M. Serum total and free sialic acid in patients with chronic liver disease. Clin Chem Lab Med 2010; 48: 137-9.